68Ga-DOTATATE Neuroblastoma Imaging Pilot

Sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Study ID
NCT04559217
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - 21 Years
Healthy Volunteers
Not accepted

Interventions

  • Radiopharmaceutical 68Ga-DOTATATE — BIOLOGICAL
    Injection of 68Ga-DOTATATE followed by PET/CT acquisition

Study Details

Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.

Key Dates

First listed
Sep 22, 2020
Start date
Dec 6, 2021
Status verified
May 2026
Primary completion
Dec 15, 2027
Completion
Sep 30, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Single arm with 68Ga-DOTATATE
    all participants will undergo a PET scan with 68Ga-DOTATATE

Primary Outcome Measure

Accrual rate [ Time Frame: For the duration of the study, lasting 6 years ]

Central Contacts

Find similar trials

Nationwide
Neuroblastoma trialsOncology trialsPediatric oncology trials

Related Studies